Pricing Trainings

All trainings are very interactive, with emphasis on reflection and peer-learning to enable you to turn the learning into action.

Become a Certified Pricing Manager

Successful pricing organizations have a clear roadmap.

The CPM programme helps

Sign-up and take full advantages of ALL membership benefits !

ArrowArrow
ArrowArrow
Slider

Welcome to EPP.

At The Heart of Pricing

 

Follow us on :

    
    

Watch us on :  

  forums
  pricing academy

Read news   : 
EPP BLOG

EPP Connect - selection of quality pricing articles, followed by quality readers.

Latest Articles
  • Membership
  • Learning
  • Learning

    All pricing training programmes to accelerate your pricing career.

    EPP is the number one learning platform for pricing professionals worldwide.

  • Certification
  • Certification

    We invite you to discover how the EPP CPM programme accelerates your pricing career

  • Events
  • Events

    AT THE HEART OF PRICING.

    EPP Pricing Forums are must-do events for pricing practitioners with high level speakers, topics and interactive formats for optimal knowledge sharing, discussion and reflection.

  ADVERTISEMENT

 

Interesting Masterclass !   

         

Join the worlds leading organisations

  • NovusCPQ Logo250x
  • Gartner
  • telenor
  • schibsted
  • HARTMANN Logo Two Color PMS 280 Blue and Warm Red
  • poclainhydraulics-newlogo
  • download
  • Michelin-logo-4000x
  • airbus helicopters flat rgb
  • Electrolux-logo-
  • tui-logo
  • bpost
  • Logo Costa Crociere
  • barco
  • px-3M wordmark.svg
  • Trelleborg Unternehmen logo.svg
  • px-Logo der Bayer AG.svg
  • Logo SAINTGOBAIN RVB
  • px-Husqvarna logo.svg
  • gkn-logo
  • Perstorp.svg
  • getinge-logo
  • Randstad
  • bridgestone
  • Borealis logo notagline-page-
  • Open-website-Lanxess
  • Philips
  • biogen
  • baxter
  • airbus helicopters flat cmyk
  • actelion
  • actavis
  • abbott-logo

European Pricing Blog
Latest news

March 2019

Delinking Prices: the future of Pharma and MedTech pricing?

There’s a core contradiction at the heart of most Pharma and MedTech companies: while their mission statements talk about “transforming lives” (Roche), “saving and sustaining lives” (Baxter), “making the world healthier” (Philips), and “contributing to human welfare” (Medtronic), often the very high prices for innovative drugs, devices and therapies limit the number of patients who can benefit.  The justification for high prices is often the need to have sufficient funds for R&D.  The tension this causes creates political pressures to change the rules for drug and medical device pricing. What to do? One idea that has some promise is “delinking” pricing for the R&D from the price of the physical product: payers would pay for the R&D separately from the consumed pill or device. How would this work? In the pure form, a manufacturer would agree with a health care payer (government, insurance company, etc.) to provide access to a drug, device or therapy for a potentially unlimited number of patients for a fixed number of years for a fixed amount.  You might think of this as Netflix Pricing for Healthcare, or Deutsche Bahn ‘Bahncard 100’, giving unlimited travel on the Germany railway network for a year.   For a hybrid version, a ‘per unit’ charge would also apply to cover the manufacturing cost of each unit (with a reasonable margin on top).  An analog for this might be Car Sharing, with an annual subscription plus a per-mile fee, or ‘Bahncard 50’, giving 50% off German rail travel for a year. Let’s try an example, with traditional, fixed payment and hybrid pricing approaches.  In the traditional pricing approach, each pill has a price. In the US this can easily top $50,000 per month for novel cancer therapies, limiting the number of patients who can benefit without breaking the healthcare budget. In pure ‘Netflix’ fixed pricing, the manufacturer might agree to a fixed payment (let’s stay $100 million) for 5 years of access to all the patients in the country that meet certain criteria. And for ‘car sharing’ hybrid pricing, perhaps the fixed price would be $50 million for 5 years, but with the price per month of treatment dropping to $5,000 to cover the cost of the pill manufacture (often gross margins for new products are very high). What are the advantages of Delinked prices? Why would governments and other payers go for this?  For the payer this gives them a much better handle on the costs, eliminating or reducing the risk of a successful product blowing their limited healthcare budget.  Crucially it enables them to make the product available to a much larger number of patients.  But what about the manufacturer?  I’d argue this scheme would help them to get back ‘on-side’ with the public about the cost of healthcare (averting more brute-force price controls for example).  They’d make strong profits from successful R&D efforts (and can still make great profits from successful blockbuster products), but those products would be much easier to distribute widely at low (or zero) incremental cost.  This delinking would also enable companies to focus on R&D: manufacturing of the actual products could in some cases be spun off to contract manufacturers (think Apple and Foxconn).  The need for expensive marketing and sales efforts significantly diminishes.  And finally, they would be much closer to living up to their mission statements! Of course there are substantial barriers and risks: waste can be a problem if the consumable is free or very low price; therapies treating more than one disease will be a challenge (as they are today), and controls over distribution will be needed.  And it will only work for products with high R&D costs and low consumable cost. Delinking in action  The ‘Netflix’ approach is being used in Australia for Hepatitis C treatments from Gilead, AbbVie, Bristol Myers Squibb and Merck: in 2015 they signed a A$1B for a 5 year “all the medicine they can use” contract (Louisiana is negotiating a similar deal).  Australia has been able to treat 7x the number of patients that would have otherwise been possible. Conclusion I believe this has huge promise for therapies that have high R&D and much lower manufacturing costs, which can benefit relatively large populations.   And while there are clearly challenges, these appear much more tractable than those associated with risk-sharing schemes that have been trailed for several years but never seem to take-off.  Finding a win-win for high pharma and MedTech prices is becoming urgent: delinked pricing seems to offer one attractive option that’s worth exploring.   By Ian Tidswell Register here for the MedTech Pricing and Market Access Training

February 2019

6 keysteps to create and capture value in medtech

    Success in the Medical Technology industry requires constant innovation. But capturing a fair share of the value (pricing) from that innovation throughout the product lifecycle is especially challenging given multiple market access hurdles, constrained healthcare budgets and diverse stakeholders to please.  The infographic below outlines the 6 steps to creating and capturing value in MedTech, from offer design through market access and reimbursement approval to new product transitions. For each step it highlights some of the key concepts and tools.  These steps will be discussed in detail during the MedTech Pricing and Market Access Strategy and Tactics training. Covering both industry-wide challenges and your specific improvement opportunities, you'll leave with an understanding of how leading companies are achieving success with pricing, and the confidence to tackle all your pricing challenges.